The CAD group showed significantly higher use of ARBs/ACEIs, CCBs, β-blockers, statins, sulfonylureas (SUs), biguanides, and dipeptidyl peptidase-4 inhibitors (DPP-4Is) than the non-CAD group. This evidence concerns the gene DPP4 and coronary artery disorder.